cdk7 in 7

CDK7-IN-7, a highly potent and selective inhibitor of CDK7 kinase, exhibits remarkable activity with an IC50 of less than 50 nM.

CDK7-IN-13 (compound 1) is an effective CDK7 inhibitor for investigating cancers associated with transcriptional dysregulation.

CDK7-IN-14 (compound 3) is a pyrimidine-derived CDK7 inhibitor applicable for studying cancers associated with transcriptional dysregulation.

CDK7-IN-18 (Compound 15) is a pyrimidine-derived CDK7 inhibitor suitable for studying cancers with transcriptional dysregulation.

CDK7-IN-17 (compound 11) is a pyrimidine-derived CDK7 inhibitor for studying transcription-disrupted cancers.

CDK7/9-IN-1 is a specific inhibitor of cyclin-dependent kinases 7/9 (CDK7/9), targeting CDK7 with IC50 values of 0.0656 μM without pre-incubation and 0.00574 μM after 3 hours pre-incubation, and displaying inhibitory activity against CDK9 with an IC50 of 2.14 μM after 3 hours pre-incubation, making it valuable for cancer research.

CDK7ligand 1 serves as an active control ligand for CDK7ligand 2. CDK7ligand 2 is a ligand for CDK7 and can be used in the synthesis of PROTACs.

CDK7/9 tide is a peptide substrate for CDK7 or CDK9[1].

CDK7/12-IN-1 is a selective inhibitor of CDK7 (IC50: 3 nM) and CDK12 (IC50: 277 nM) and effectively inhibits tumor growth.

CDK7 ligand 2 (Compound A6) is a CDK7 ligand utilized in the synthesis of PROTACs.

CDK7-IN-31 (compound 13) is an effective and orally active inhibitor of cyclin-dependent kinase 7 (CDK7) with a dissociation constant (Kd) of 0.18 nM. This compound exhibits anticancer activity.

CDK7-IN-27 (Compound 37) is a selective inhibitor of cyclin-dependent kinase 7 (CDK7), with a Ki value of 3 nM. It effectively causes cell cycle arrest at the G0/G1 phase.

Olomoucine II is a potent cyclin-dependent kinase inhibitor with IC50 values of 7.6, 0.1, 19.8, 0.45, and 0.06 μM for CDK1, CDK2, CDK4, CDK7, and CDK9, respectively. Olomoucine II demonstrates high selectivity over numerous other kinases while retaining measurable activity against ERK2 and ABCB1, allowing it to modulate multidrug resistance pathways. Olomoucine II suppresses proliferation across cancer cell lines regardless of p53 status and exhibits synergistic action with daunorubicin in ABCB1-expressing HCT-8 cells.Olomoucine II additionally inhibits replication of HSV-1, HSV-2, vaccinia virus, adenovirus 4, and human CMV, making Olomoucine II an important antiviral and anticancer research tool.

CDK7-IN-5, a CDK7 inhibitor with an IC 50 value of less than 100 nM, exhibits potent anticancer properties (WO2015154022A1, Compound 104).

CDK7-IN-1 is an analog derived from YKL-5-124 and functions as an inhibitor of cyclin-dependent kinase 7 (cdk7). It exhibits strong inhibitory activity, with an IC50 value of less than 100 nM (WO 2016105528 A2, Compound 215).

CDK7-IN-2 hydrochloride hydrate (Example 6) is a potent and specific inhibitor of the CDK7 enzyme, exhibiting significant anti-cancer properties.

CDK7-IN-6 is a highly effective and specific inhibitor (IC50 ≤100 nM) of cyclin-dependent kinase 7 (CDK7). It showcases remarkable selectivity, with more than a 200-fold preference for CDK7 over CDK1, CDK2, and CDK5. This compound holds significant potential for cancer research purposes.

CDK7-IN-16 (Compound 9) is a potent inhibitor of CDK 7 (IC50: 1-10 nM). CDK7-IN-16 can be used in research against cancer, particularly cancers with transcriptional abnormalities.

CDK7-IN-20 is a potent, selective, and irreversible inhibitor of Cyclin-Dependent Kinase 7 (CDK7) with an IC50 value of 4 nM, exhibiting over 206-fold selectivity against related kinases [CDK1, CDK2, CDK3, CDK5, CDK6, CDK9, and CDK12]. It holds potential for research into autosomal dominant polycystic kidney disease (ADPKD).

CDK7-IN-25 (CY-16-1) is a highly potent CDK7 inhibitor with an IC50 of less than 1nM, used in cancer research [1].

HDAC1/CDK7-IN-1 (compound 8e) is a dual inhibitor of CDK7 and HDAC1, with IC50 values of 893 nM and 248 nM, respectively. It suppresses the proliferation of cancer cell lines such as MDA-MB-231, MCF-7, A549, and HCT-116, induces cell cycle arrest and apoptosis in HCT-116 cells, and impedes their migration [1].